Zanamivir: From drug design to the clinic

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 356, Issue 1416, 2001, Pages 1885-1893

  Elliott, Michael ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Influenza; Neuraminidase inhibitors; Zanamivir

Indexed keywords

INFLUENZA;

ANTIVIRUS AGENT; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; PYRAN DERIVATIVE; SIALIC ACID DERIVATIVE; SIALIDASE; ZANAMIVIR;

ANIMAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; DRUG INTERACTION; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; METHODOLOGY; MULTIDRUG RESISTANCE; REVIEW;

ANIMALS; ANTIVIRAL AGENTS; CHEMOPREVENTION; CLINICAL TRIALS; DRUG DESIGN; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE, VIRAL; ENZYME INHIBITORS; GUANIDINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; NEURAMINIDASE; PYRANS; SIALIC ACIDS; ZANAMIVIR;

EID: 0035969780     PISSN: 09628436     EISSN: None     Source Type: Journal    
DOI: 10.1098/rstb.2001.1021     Document Type: Conference Paper

References (45)

1. Resistance of influenza A virus to amantadine and rimantadine: Results of one decade of surveillance
2. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers
3. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir
4. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers
5. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir
6. Preclinical disposition studies of GG167, a novel anti-influenza agent
7. The low potential for drug interactions with zanamivir
8. Preclinical development of low toxicity drugs: Focus on zanamivir, an anti-influenza drug
9. Zanamivir: A review of clinical safety
10. A multicentre prospective double-blind controlled trial comparing the relative safety of zanamivir to rimantadine for nursing home influenza outbreak control
11. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en
12. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus
13. Amantadine and rimantadine resistance in influenza A viruses
14. Comparative toxicity of amantadine hydrochloride and rimantadine hydro-chloride in healthy adults
15. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics
16. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families
17. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium
18. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza
19. Efficacy of intranasal zanamivir in experimental human influenza A and B virus infection
20. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections
21. Inhaled zanamivir for the prevention of influenza in families
22. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: A randomized controlled trial
23. Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position
24. Zanamivir for the treatment of clinically diagnosed influenza in clinical practice: Results of the Valuable-Insights-from-Patients study
25. The efficacy and safety of inhaled zanamivir in the treatment of influenza in otherwise healthy and high risk individuals in North America
26. Zanamivir for the treatment of influenza A and B infection in high-risk patients - A pooled analysis of randomized controlled trials
27. The impact and cost of influenza in the elderly
28. Resistance of influenza viruses to neuraminidase inhibitors - A review
29. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: A randomized, double-blind, placebo-controlled European study
30. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: Results from Japan
31. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections
32. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: Pooled efficacy analysis
33. Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial
34. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease - A double-blind, randomised, placebo-controlled, multicentre study
35. Clinical efficacy of inhaled zanamivir for the treatment of patients with influenza B virus infection
36. Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation
37. Pharmacokinetics and tolerability of a single inhaled dose of zanamivir in children
38. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase)
39. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets
40. Zanamivir, a new targeted therapy in the treatment of influenza - A patient perspective assessed by questionnaire
41. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections
42. Rational design of potent sialidase-based inhibitors of influenza virus
43. Recent developments in antiviral therapy of influenza
44. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro
45. Influenza, influenza vaccine and amantadine/rimantadine